A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Read full text Summarise with VIRAT
Authors: Novartis
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Fields of Study & Subjects

Retinal Diseases and Treatments Ocular Diseases and Behçet’s Syndrome Retinal and Macular Surgery

Publication details

Journal / source
Vivli
Publication date
27 March 2026
Language
EN
Document type
Dataset